ライフサイエンスコーパス: transitional cell

1 ation of acinar cells to the nestin-positive transitional cell.

2 superficial endocardial layer of atrial and transitional cells.

3 of large-sized cells somewhat similar to the transitional cells.

4 band of well-polarized but poorly excitable transitional cells.

5 artment, enriched for CXCL13-responsive late transitional cells.

6 is higher than that of mesothelial cells and transitional cells.

7 iated with the appearance of nestin-positive transitional cells.

8 native pathway, the survival of neonatal B-1 transitional cells and their maturation into B-1 B cells

9 lar B cells in splenic development, immature transitional cells are an essential component for unders

10 However, transitional cells are larger and have an overall less d

11 Some transitional cells are supporting cells participating in

12 Fifteen patients with recurrent superficial transitional cell bladder carcinoma who experienced prio

13 ammary and prostate cancers, the majority of transitional cell bladder tumors showed Id1 protein expr

14 exhibits significant activity in metastatic transitional cell cancer with minimal toxicity, but surv

15 ificant risk factor for EN and its attendant transitional cell cancer.

16 ed EN, (ii) these adducts can be detected in transitional cell cancers, and (iii) A:T --> T:A transve

17 onstrated absent or greatly reduced pinin in transitional cell carcinoma (TCC) and RCC tumors.

18 y culture (P0) and after passage in vitro of transitional cell carcinoma (TCC) biopsies that represen

19 ghly tumorigenic and highly metastatic human transitional cell carcinoma (TCC) cell line 253J B-V ove

20 ltetrazolium bromide (MTT) assays in bladder transitional cell carcinoma (TCC) cell lines RT4 and SW7

21 and protein are observed among several human transitional cell carcinoma (TCC) cell lines, suggesting

22 GF) accumulates in the nucleus in aggressive transitional cell carcinoma (TCC) cells and this histolo

23 Human transitional cell carcinoma (TCC) cells are labeled with

24 ptor (BMP-R) types IA, IB, and II in bladder transitional cell carcinoma (TCC) cells.

25 IFN-alpha therapy for clinical treatment of transitional cell carcinoma (TCC) has prompted us to inv

26 Transitional cell carcinoma (TCC) is a pan-urothelial di

27 therapy surgery for patients with metastatic transitional cell carcinoma (TCC) is controversial.

28 Prostatic transitional cell carcinoma (TCC) is present in up to 48

29 of noninvasive methods for the diagnosis of transitional cell carcinoma (TCC) of the bladder remains

30 We have screened 193 cases of transitional cell carcinoma (TCC) of the bladder using 3

31 invasive method for monitoring patients with transitional cell carcinoma (TCC) of the bladder would b

32 q is the most frequent genetic alteration in transitional cell carcinoma (TCC) of the bladder, implic

33 ured biopsies of superficial and myoinvasive transitional cell carcinoma (TCC) of the bladder.

34 vement in the development and progression of transitional cell carcinoma (TCC) of the bladder.

35 9 are the most common genetic alteration in transitional cell carcinoma (TCC) of the bladder.

36 e identify a potential role for proHB-EGF in transitional cell carcinoma (TCC) of the bladder.

37 mine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower

38 ations are known to be associated with human transitional cell carcinoma (TCC) of the urinary bladder

39 eleted in many human malignancies, including transitional cell carcinoma (TCC) of the urinary bladder

40 Our microRNA profiling of bladder transitional cell carcinoma (TCC) patient samples reveal

41 orifice positive for a high-grade papillary transitional cell carcinoma (TCC) with muscularis propri

42 on forms of bladder tumors: 69 of 97 (71.1%) transitional cell carcinoma (TCC), 38 of 53 (71.6%) squa

43 Transitional cell carcinoma (TCC), a neoplasm of urinary

44 remains the standard of care for metastatic transitional cell carcinoma (TCC), but its limitations i

45 predominant component in the development of transitional cell carcinoma (TCC), but the particular pa

46 Transitional cell carcinoma (TCC), the most common cance

47 potential as an immunotherapeutic target in transitional cell carcinoma (TCC).

48 dies demonstrated chromosome 3p deletions in transitional cell carcinoma (TCC).

49 be well tolerated in patients with advanced transitional cell carcinoma (TCC).

50 proven modality for treatment of upper-tract transitional cell carcinoma (TCC).

51 invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node-negative, 1

52 In the SCID-beige mice, T24 human bladder transitional cell carcinoma also was used as the tumor i

53 he current fund of knowledge about prostatic transitional cell carcinoma and the implications for dia

54 ntly it has been shown to be a human bladder transitional cell carcinoma cell line.

55 n of p27(Kip1) and cyclin E in human bladder transitional cell carcinoma cells correlates with advanc

56 chemotherapy in advanced upper urinary tract transitional cell carcinoma continue to evolve and remai

57 F-7, pancreatic carcinoma (CRL 1420, bladder transitional cell carcinoma EJ, and melanoma LOX) but no

58 The operative management of invasive transitional cell carcinoma has advanced significantly i

59 onsidered related to the study drug (bladder transitional cell carcinoma in the ozanezumab group and

60 ase 2 trial, we enrolled patients with T2-4a transitional cell carcinoma of the bladder at 24 medical

61 Patterns of RT112 cells derived from a transitional cell carcinoma of the bladder could be depo

62 Rb) expression was evaluated in 185 cases of transitional cell carcinoma of the bladder from patients

63 Transitional cell carcinoma of the bladder is a common m

64 Transitional cell carcinoma of the bladder is comprised

65 erin and interferon are clinically active in transitional cell carcinoma of the bladder, but their me

66 ir derived cell lines from two patients with transitional cell carcinoma of the bladder.

67 nti-Yo antibody response in association with transitional cell carcinoma of the bladder.

68 n a wide variety of human cancers, including transitional cell carcinoma of the bladder.

69 27(Kip1) and cyclin E, in the progression of transitional cell carcinoma of the bladder.

70 s the standard treatment for muscle-invasive transitional cell carcinoma of the bladder.

71 th bacille Calmette-Guerin (BCG) -refractory transitional cell carcinoma of the bladder.

72 Transitional cell carcinoma of the renal pelvis or dista

73 In a patient with transitional cell carcinoma of the renal pelvis, hydrone

74 We present four cases of transitional cell carcinoma of the transplant ureter (TC

75 rectomy has been the treatment of choice for transitional cell carcinoma of the upper urinary tract.

76 lear cell) renal carcinoma (11 of 11 cases), transitional cell carcinoma of the urinary bladder (6 of

77 ssue sections of canine spontaneous invasive transitional cell carcinoma of the urinary bladder (a mo

78 s accrued from patients with muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-

79 COX-1 and COX-2 expression in human invasive transitional cell carcinoma of the urinary bladder by im

80 of chromosome 3 was conducted in 72 cases of transitional cell carcinoma of the urinary bladder using

81 n pet dogs with naturally occurring invasive transitional cell carcinoma of the urinary bladder.

82 oving the precision of the estimated risk of transitional cell carcinoma of the urinary tract associa

83 n of the bladder tumor and biopsy identified transitional cell carcinoma or urothelial carcinoma inva

84 Transitional cell carcinoma should be considered in pati

85 Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells

86 Using a murine transitional cell carcinoma tumor model, MB49, which nat

87 We measured DNA methylation in 342 transitional cell carcinoma tumors at BCL2, PTGS2 (COX2)

88 Additionally, transitional cell carcinoma was observed in approximatel

89 % of the K5.COX-2 transgenic mice; no TCH or transitional cell carcinoma was observed in wild-type bl

90 of 31 consecutive patients with renal pelvic transitional cell carcinoma were evaluated.

91 Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored hepa

92 ickening in four patients (three of whom had transitional cell carcinoma), a renal abscess, a coloves

93 ses, 24 were renal cell carcinoma, one was a transitional cell carcinoma, and one was an angiomyolipo

94 Forty-three patients had transitional cell carcinoma, and six had squamous cell c

95 sing an early-stage renal cell carcinoma and transitional cell carcinoma, chronic lymphocytic leukemi

96 ancer, testis cancer and upper urinary tract transitional cell carcinoma, no recently published study

97 sic fibroblast growth factor (bFGF) in human transitional cell carcinoma, reduce its angiogenesis, an

98 identified as a region of non-random LOH in transitional cell carcinoma, suggesting the presence of

99 In transitional cell carcinoma, the most common form of bla

100 st described in 1991 for upper urinary tract transitional cell carcinoma, with long-term data now eme

101 inoma, adult polycystic kidney disease or in transitional cell carcinoma.

102 atment of organ-confined upper urinary tract transitional cell carcinoma.

103 Of patients with transitional-cell carcinoma (n = 776), LVI status was av

104 ed as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder.

105 d primarily patients with non-organ-confined transitional-cell carcinoma (TCC) of the bladder.

106 nd carboplatin for the treatment of advanced transitional-cell carcinoma (TCC) of the urothelium has

107 in previously treated patients with advanced transitional-cell carcinoma (TCC) of the urothelium.

108 previously untreated patients with advanced transitional-cell carcinoma (TCC) to assess its efficacy

109 eported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic

110 icacy and toxicity in patients with advanced transitional-cell carcinoma (TCC) who had failed to resp

111 ymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July

112 Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not

113 STT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1

114 al urotoxicity, including the development of transitional-cell carcinoma of the urinary bladder.

115 Seven patients (5%) developed transitional-cell carcinoma of the urinary bladder.

116 ond-line treatment of patients with advanced transitional-cell carcinoma of the urothelial tract.

117 overall survival for patients with advanced transitional-cell carcinoma of the urothelium.

118 in patients with unresectable or metastatic transitional-cell carcinoma.

119 line therapy and emerging drugs for advanced transitional-cell carcinoma.

120 tment has an antitumor effect in superficial transitional-cell carcinoma.

121 y included 59 well-characterized superficial transitional cell carcinomas (Ta, n = 28; T1, n = 31) fo

122 pure squamous cell carcinomas (SCC), and in transitional cell carcinomas (TCC) of the bladder with S

123 five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of the renal pelvis a

124 FGFR3 coding sequence from 63 transitional cell carcinomas (TCC) of various stages and

125 elial carcinomas, including 28 pTa low-grade transitional cell carcinomas (TCC), 31 pTa high-grade TC

126 b and p53 pathway alterations in 12 invasive transitional cell carcinomas (TCCs) and addressed the fu

127 A survey of 50 transitional cell carcinomas (TCCs) revealed a UP-II pol

128 and nature of FGFR3 mutations in a panel of transitional cell carcinomas and cell lines and studied

129 PDE5 was overexpressed in human squamous and transitional cell carcinomas compared with normal urothe

130 ylation of four CpG islands in human urinary transitional cell carcinomas of different stages and gra

131 ed that around one-third (33/101) of primary transitional cell carcinomas of the bladder overexpress

132 More than 50% of transitional cell carcinomas of the bladder show loss of

133 ation of these genes by analyzing 69 primary transitional cell carcinomas of the bladder with a panel

134 but was detected in 25 of 29 (86%) invasive transitional cell carcinomas of the urinary bladder and

135 ity, we have studied a cohort of superficial transitional cell carcinomas of the urinary bladder by i

136 ed the pattern of allelic imbalance in human transitional cell carcinomas of the urinary bladder incl

137 NU plus H202 or H202 alone formed high-grade transitional cell carcinomas when injected into nude mic

138 g water and the incidence of urinary bladder transitional cell carcinomas.

139 microsatellite loci in 20 grade III invasive transitional cell carcinomas.

140 adder proliferative lesions, including three transitional cell carcinomas.

141 ssues and normal mammary tissues and bladder transitional cell carcinomas.

142 Transitional cells, coexpressing hair cell and supportin

143 as defined by expression of alpha-SM actin) "transitional" cells, coexpressing both endothelial and S

144 "Transitional" cells, coexpressing both endothelial marke

145 Putative ER(+)PR(+)CK5(+) transitional cells could be seen only in colonies or tum

146 ly Walthard cell nests represent urothelial (transitional cell) differentiation.

147 d thymocytes paradoxically appear as CD4+8lo transitional cells during their differentiation into CD8

148 specimens, as well as 11 cases of low-grade transitional cell dysplasia, 21 cases of carcinoma in si

149 The transitional cells exhibit a similar apical-basal polari

150 mRNA was observed in proliferating oval and transitional cells, forming duct-like structures of cyto

151 TACI(+) transitional cells from BAFF-transgenic mice are charact

152 Patients with non-transitional-cell histology, poor performance status, an

153 a keratin 5 promoter, is sufficient to cause transitional cell hyperplasia (TCH) in 17% and 75% of th

154 hocytes are thought to develop from immature transitional cells in a BCR-dependent manner.

155 een proposed that these oval cells represent transitional cells in a nonhepatocytic liver facultative

156 the risk allele, due to an expansion of late transitional cells in a stage targeted by selection mech

157 markers, suggest that CK19+/NCAM+ cells are transitional cells in the biliary lineage and that rare

158 that are negative for all three markers are transitional cells in the hepatocytic lineage.

159 onstrate that B-1 B cells are generated from transitional cell intermediates that emerge in a distinc

160 Akap12-/- prostate lobes suggests that these transitional cells may be the source of the lymph node m

161 Severe B-cell deficiency affects mature and transitional cells, mimicking the action of rituximab.

162 or, proHB-EGF, localizes to the cytoplasm of transitional cells of the human bladder urothelium and t

163 hway and allowing circus movement within the transitional cells of the posterior AV nodal connection.

164 w that, in contrast to the dependence of B-2 transitional cells on the alternative pathway, the survi

165 A transitional cell population, defined by the first downr

166 r ~2 wk after birth and then declines as B-2 transitional cells predominate.

167 gest that hFLMPCs are mesenchymal-epithelial transitional cells, probably derived from mesendoderm.

168 Cases included 76 renal cell, 24 transitional cell renal pelvis and ureter, and 22 other

169 Transitional cells represent a crucial step in the diffe

170 ed, among the oval cells, a subpopulation of transitional cells showing features of maturing hepatocy

171 A continuum of transitional cell states exists between these discrete s

172 e bacterial QIRs were harbored in underlying transitional cells, stimulation of epithelial turnover t

173 isthmal) zone of the gastric unit and become transitional cells (TCs) with molecular and ultrastructu

174 auses loss of parietal cells, development of transitional cells that express markers of mucus neck an

175 ntative sample of normal and malignant human transitional cell tissues.

176 s of carcinoma in situ (CIS), 38 superficial transitional cell tumors (STCC, stages T(a)-T(1)), 65 mu

177 NA expression in two of five muscle-invasive transitional cell tumors when compared with normal sampl

178 that SHPCs may represent an intermediate or transitional cell type between oval cells and mature hep

179 A transitional cell type from the submesothelial cell phen

180 is regimen in patients with both TCC and non-transitional-cell urothelial tumors is ongoing.

181 renal failure and a strong association with transitional cell (urothelial) carcinoma of the upper ur

182 lear outer sulcus cells (OSC) and vestibular transitional cells (VTC) are part of the parasensory epi

183 acterized by a preponderance of immature and transitional cells, whose persistence was associated wit

184 n controls, and an increase in the number of transitional cells with a CD4+CD8low phenotype.